2.53
-0.17(-6.30%)
Currency In USD
| Previous Close | 2.7 |
| Open | 2.8 |
| Day High | 2.81 |
| Day Low | 2.52 |
| 52-Week High | 4.1 |
| 52-Week Low | 1.72 |
| Volume | 21,566 |
| Average Volume | 46,866 |
| Market Cap | 6.54M |
| PE | -0.45 |
| EPS | -5.63 |
| Moving Average 50 Days | 2.36 |
| Moving Average 200 Days | 2.43 |
| Change | -0.17 |
If you invested $1000 in GT Biopharma, Inc. (GTBP) since IPO date, it would be worth $2.99 as of May 30, 2025 at a share price of $2.53. Whereas If you bought $1000 worth of GT Biopharma, Inc. (GTBP) shares 4 years ago, it would be worth $26.11 as of May 30, 2025 at a share price of $2.53.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals
GlobeNewswire Inc.
May 19, 2025 1:00 PM GMT
Following the formal safety review of Cohort 1, no safety or tolerability issues were observed, allowing the company to move forward with Cohort 2. The company plans on releasing more detailed results from Phase 1 later in 2025 following completion o
GT Biopharma Appoints New Member to its Board of Directors
GlobeNewswire Inc.
May 14, 2025 11:00 AM GMT
SAN FRANCISCO, CALIFORNIA, May 14, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural
GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit
GlobeNewswire Inc.
Mar 04, 2025 12:00 PM GMT
SAN FRANCISCO, CALIFORNIA, March 04, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natura